08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

ACT Biotech, Eddingpharm deal

Eddingpharm acquired exclusive, worldwide rights to develop and commercialize oncology compounds telatinib, ACTB1003 and ACTB1010 from ACT Biotech. Eddingpharm said the deal includes "several hundred" compounds from the same family as the three...
07:00 , May 9, 2011 |  BioCentury  |  Emerging Company Profile

ACT: ACTing selectively

Tyrosine kinase inhibitors that target VEGF receptor have revolutionized the treatment of renal cell carcinoma (RCC). However, off-target effects have resulted in little success of the first-generation drugs in other solid tumors aside from two...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Clinical News

ACTB1003: Phase I start

This half, ACT will begin a dose-escalation Phase I trial to evaluate oral ACTB1003 in about 20 patients. ACT Biotech Inc., San Francisco, Calif.   Product: ACTB1003   Business: Cancer   Molecular target: NA   Description: Oral kinase...